Xeris Biopharma Holdings Inc (XERS)
2.24
-0.02
(-0.88%)
USD |
NASDAQ |
Jun 28, 16:00
2.245
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Cash from Investing (Quarterly): -19.65M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -19.65M |
| December 31, 2023 | 14.87M |
| September 30, 2023 | 14.66M |
| June 30, 2023 | 8.452M |
| March 31, 2023 | -43.98M |
| December 31, 2022 | 9.168M |
| September 30, 2022 | 6.709M |
| June 30, 2022 | 11.87M |
| March 31, 2022 | 6.716M |
| December 31, 2021 | 36.60M |
| September 30, 2021 | 18.50M |
| June 30, 2021 | 16.56M |
| March 31, 2021 | 26.30M |
| December 31, 2020 | 7.249M |
| September 30, 2020 | -60.67M |
| Date | Value |
|---|---|
| June 30, 2020 | 17.34M |
| March 31, 2020 | 8.676M |
| December 31, 2019 | -9.041M |
| September 30, 2019 | -2.496M |
| June 30, 2019 | 27.88M |
| March 31, 2019 | -18.72M |
| December 31, 2018 | -11.72M |
| September 30, 2018 | -56.05M |
| June 30, 2018 | -0.156M |
| March 31, 2018 | -0.333M |
| December 31, 2017 | -0.236M |
| September 30, 2017 | -0.025M |
| June 30, 2017 | -0.097M |
| March 31, 2017 | -0.342M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-60.67M
Minimum
Sep 2020
36.60M
Maximum
Dec 2021
3.570M
Average
8.676M
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
| AVITA Medical Inc | 15.07M |
| INmune Bio Inc | -- |
| NovaBay Pharmaceuticals Inc | 1.068M |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 1.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.30M |
| Cash from Financing (Quarterly) | 35.19M |
| Free Cash Flow | -43.38M |
| Free Cash Flow Per Share (Quarterly) | -0.1457 |
| Free Cash Flow to Equity (Quarterly) | -59.21M |
| Free Cash Flow to Firm (Quarterly) | -15.27M |
| Free Cash Flow Yield | -13.98% |